CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Routine Continuous Electrocardiographic Monitoring Following Percutaneous Coronary Interventions Optimal Stenting Technique for Complex Coronary Lesions Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation Contrast-Associated Acute Kidney Injury and Serious Adverse Outcomes Following Angiography Spontaneous Coronary Artery Dissection: JACC State-of-the-Art Review Select Drug-Drug Interactions With Direct Oral Anticoagulants Poor R-wave progression as a predictor of sudden cardiac death in general population and subjects with coronary artery disease Dynamic atrioventricular delay programming improves ventricular electrical synchronization as evaluated by 3D vectorcardiography Coronary Plaque Features on CTA Can Identify Patients at Increased Risk of Cardiovascular Events

Original Research2017 Nov 14;70(20):2504-2515.

JOURNAL:J Am Coll Cardiol. Article Link

A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration

Natsumeda M, Florea V, Hare JM et al. Keywords: allogeneic; cardiac stem cell; ischemic cardiomyopathy; mesenchymal stem cell

ABSTRACT


BACKGROUND - The combination of autologous mesenchymal stem cells (MSCs) and cardiac stem cells(CSCs) synergistically reduces scar size and improves cardiac function in ischemic cardiomyopathy. Whereas allogeneic (allo-)MSCs are immunoevasive, the capacity of CSCs to similarly elude the immune system remains controversial, potentially limiting the success of allogeneic cell combination therapy (ACCT).


OBJECTIVES - This study sought to test the hypothesis that ACCT synergistically promotes cardiac regenerationwithout provoking immunologic reactions.


METHODS - Göttingen swine with experimental ischemic cardiomyopathy were randomized to receive transendocardial injections of allo-MSCs + allo-CSCs (ACCT: 200 million MSCs/1 million CSCs, n = 7), 200 million allo-MSCs (n = 8), 1 million allo-CSCs (n = 4), or placebo (Plasma-Lyte A, n = 6). Swine were assessed by cardiac magnetic resonance imaging and pressure volume catheterization. Immune response was tested by histologic analyses.


RESULTS - Both ACCT and allo-MSCs reduced scar size by -11.1 ± 4.8% (p = 0.012) and -9.5 ± 4.8% (p = 0.047), respectively. Only ACCT, but not MSCs or CSCs, prevented ongoing negative remodeling by offsetting increases in chamber volumes. Importantly, ACCT exerted the greatest effect on systolic function, improving the end-systolic pressure-volume relation (+0.98 ± 0.41 mm Hg/ml; p = 0.016). The ACCT group had more phospho-histone H3+ (a marker of mitosis) cardiomyocytes (p = 0.04), and noncardiomyocytes (p = 0.0002) than did the placebo group in some regions of the heart. Inflammatory sites in ACCT and MSC-treated swine contained immunotolerant CD3+/CD25+/FoxP3+ regulatory T cells (p < 0.0001). Histologic analysis showed absent to low-grade inflammatory infiltrates without cardiomyocyte necrosis.


CONCLUSIONS - ACCT demonstrates synergistic effects to enhance cardiac regeneration and left ventricular functional recovery in a swine model of chronic ischemic cardiomyopathy without adverse immunologic reaction. Clinical translation to humans is warranted.


Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.